Udo Ubani

[90] Fonollosa, A., Segura, A., Giralt, J., & Garcia-Arumi, J. (2007). Tuberculous uveitis af‐ ter treatment with etanercept. *Graefes Arch Clin Exp Ophthalmol*, 245(9), 1397-9.

[91] Zaher, S. S., Sandinha, T., Roberts, F., et al. (2005). Herpes Simplex Keratitis Misdiag‐ nosed as Rheumatoid Arthritis-Related Peripheral Ulcerative Keratitis. *Cornea*, 24(8),

[92] Bourcier, T., Thomas, F., Borderie, V., et al. (2003). Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases. *Br J Ophtalmol*, 87, 834-838.

[93] Schafer, F., Bruttin, O., Zografos, L., et al. (2001). Bacterial keratitis: a prospective

[94] Hearter, G., Manfras, B. J., de jong-Hesse, Y., et al. Cytomegalovirus retinitis in pa‐ tient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid

clinical and microbiological study. *Br J Ophtalmol*, 85, 842-847.

arthritis. *Clin. Infect.Dis*, 39(9), 88-94.

1015-1017.

230 Common Eye Infections

Additional information is available at the end of the chapter

http://dx.doi.org/10.5772/53861

**1. Introduction**

Trachoma is the leading infectious cause of preventable blindness in the world today and occurs as mesoendemic, endemic, or hyperendemic disease. The distribution is primarily in tropical developing countries of the world including North and sub-Saharan Africa, the Middle East, and the Northern Indian subcontinent. The disease has also been reported in Southeast Asia and specific regions of Central and South America, Australia, and the South Pacific Islands. Of the more than 600 million people afflicted, approximately 150 million have visual deficits, and 12 million are predicted to be blind by the year 2020.
